The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...